Market in sight for Pharmaxis
Wednesday, 20 August, 2008
Pharmaxis [ASX: PXS] has concluded a Phase 3 clinical trial of its Bronchitol treatment, confirming its safety in subjects with bronchiectasis.
None of the 99 subjects who concluded the trial experienced serious adverse effects attributable to the drug, even after a 12-month treatment schedule.
Some minor side effects were attributable to the medication, such as coughing and a sore throat, but these symptoms occurred in less than 10 per cent of the sample group.
Seven subjects did drop out of the trial after suffering adverse events – lung infections or chronic coughing – but it has not been demonstrated that Bronchitol was the cause of these effects.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
